Novel drug transporter substrates identification: an innovative approach based on metabolomic profiling, in silico ligand screening and biological validation.

[1]  Hamed Haseli Mashhadi,et al.  The International Mouse Phenotyping Consortium: comprehensive knockout phenotyping underpinning the study of human disease , 2022, Nucleic Acids Res..

[2]  G. Superti-Furga,et al.  A structure and evolutionary-based classification of solute carriers , 2022, iScience.

[3]  M. Schwab,et al.  Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation. , 2022, Pharmacology & therapeutics.

[4]  Megan L. Koleske,et al.  New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium , 2022, Clinical pharmacology and therapeutics.

[5]  L. Gong,et al.  The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms , 2022, Clinical pharmacology and therapeutics.

[6]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.

[7]  K. Maeda,et al.  Elucidation of N1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters , 2019, Drug Metabolism and Disposition.

[8]  G. Superti-Furga,et al.  A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs , 2019, bioRxiv.

[9]  B. Psaty,et al.  Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink , 2019, Clinical pharmacology and therapeutics.

[10]  M. Fromm,et al.  Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions , 2019, Clinical pharmacology and therapeutics.

[11]  Krishna R. Kalari,et al.  Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2 , 2019, Clinical pharmacology and therapeutics.

[12]  M. Fromm,et al.  Interplay of the Organic Cation Transporters OCT1 and OCT2 with the Apically Localized Export Protein MATE1 for the Polarized Transport of Trospium. , 2019, Molecular pharmaceutics.

[13]  J. Vassy,et al.  Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review , 2018, Clinical pharmacology and therapeutics.

[14]  D. Voora,et al.  Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings , 2018, Circulation. Genomic and precision medicine.

[15]  U. Hofmann,et al.  Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. , 2018, Journal of proteome research.

[16]  M. Fromm,et al.  Contribution of multidrug and toxin extrusion protein 1 (MATE1) to renal secretion of trimethylamine-N-oxide (TMAO) , 2018, Scientific Reports.

[17]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[18]  Fabian Müller,et al.  Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine. , 2017, Molecular pharmaceutics.

[19]  Ute Hofmann,et al.  Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison. , 2017, Journal of proteome research.

[20]  Tudor I. Oprea,et al.  DrugCentral: online drug compendium , 2016, Nucleic Acids Res..

[21]  S. Ekins,et al.  Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1 , 2016, Molecular Pharmacology.

[22]  M. Schwab,et al.  Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine , 2016, Archives of Toxicology.

[23]  G. Smyth,et al.  ROBUST HYPERPARAMETER ESTIMATION PROTECTS AGAINST HYPERVARIABLE GENES AND IMPROVES POWER TO DETECT DIFFERENTIAL EXPRESSION. , 2016, The annals of applied statistics.

[24]  Cynthia L. Smith,et al.  The International Mouse Strain Resource (IMSR): cataloging worldwide mouse and ES cell line resources , 2015, Mammalian Genome.

[25]  Cheng Luo,et al.  Combinatorial Pharmacophore Modeling of Multidrug and Toxin Extrusion Transporter 1 Inhibitors: a Theoretical Perspective for Understanding Multiple Inhibitory Mechanisms , 2015, Scientific Reports.

[26]  M. Schwab,et al.  Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors , 2015, The Pharmacogenomics Journal.

[27]  G. Superti-Furga,et al.  A Call for Systematic Research on Solute Carriers , 2015, Cell.

[28]  R. Yumoto,et al.  Functional Expression of PEPT2 in the Human Distal Lung Epithelial Cell Line NCl-H441 , 2015, Pharmaceutical Research.

[29]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[30]  M. Schwab,et al.  DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome , 2013, Clinical Cancer Research.

[31]  M. Hediger,et al.  The ABCs of membrane transporters in health and disease (SLC series): Introduction , 2013, Molecular aspects of medicine.

[32]  K. Inui,et al.  Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. , 2013, Molecular aspects of medicine.

[33]  Stephen A Baldwin,et al.  The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. , 2013, Molecular aspects of medicine.

[34]  Andrej Sali,et al.  Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. , 2013, Journal of medicinal chemistry.

[35]  Mikko Niemi,et al.  Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 , 2013, Genome Medicine.

[36]  K. Giacomini,et al.  Renal transporters in drug development. , 2013, Annual review of pharmacology and toxicology.

[37]  M. Schwab,et al.  Organic Anion Transporters and Their Implications in Pharmacotherapy , 2012, Pharmacological Reviews.

[38]  S. Ekins,et al.  Molecular Determinants of Ligand Selectivity for the Human Multidrug and Toxin Extruder Proteins MATE1 and MATE2-K , 2012, Journal of Pharmacology and Experimental Therapeutics.

[39]  E. van de Steeg,et al.  Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. , 2012, The Journal of clinical investigation.

[40]  J. Dye,et al.  Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 , 2011, Nature.

[41]  C. Hoffmann,et al.  Double‐transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations , 2011, British journal of pharmacology.

[42]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[43]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[44]  Carla P. Guimarães,et al.  Haploid Genetic Screens in Human Cells Identify Host Factors Used by Pathogens , 2009, Science.

[45]  T. Mizuno,et al.  Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin , 2009, Molecular Pharmacology.

[46]  Tomoko Sato,et al.  Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. , 2008, Biochemical pharmacology.

[47]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[48]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[49]  Hiroshi Omote,et al.  A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  H. Daniel,et al.  The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology , 2004, Pflügers Archiv.

[51]  R. Balling,et al.  Targeted Disruption of the Peptide Transporter Pept2 Gene in Mice Defines Its Physiological Role in the Kidney , 2003, Molecular and Cellular Biology.

[52]  K. Rajewsky,et al.  Conditional gene targeting. , 1996, The Journal of clinical investigation.

[53]  M. Hediger,et al.  Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidney. , 1995, Biochimica et biophysica acta.

[54]  H. Kusuhara,et al.  Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins , 2013, Pharmaceutical Research.

[55]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[56]  H. Koepsell,et al.  Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. , 2011, Handbook of experimental pharmacology.

[57]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .